Dutch conglomerate Royal Philips announced Tuesday that it has acquired PathXL, a Northern Ireland-based developer of software used for digital pathology image analysis, workflow and education.
An experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials.
Medical-device makers might soon have an easier time winning hefty financial damages from companies that infringe on their patents following a U.S. Supreme Court decision Monday.
Drugmaker Merck is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication.
After several years of disappointing financials, Boston Scientific Corp. is cutting costs in a global restructuring.
Zimmer Biomet Holdings, a major manufacturer of musculoskeletal devices, will buy spinal device company LDR Holding Corp. for $1 billion.
Ponder the fleeting nature of fortune. Last fall, Theranos CEO Elizabeth Holmes, 32, was deemed the “youngest self-made female billionaire” in the world by Forbes magazine. Her net worth today? Bupkis.
Physicians have increasingly looked to 3-D printing for unique implants and surgical models, and some manufacturers are now using the method to mass produce medical devices and even drugs that are more precise, customizable and biocompatible than conventionally produced products.
Edward-Elmhurst Health, based in Naperville, Ill., is investing $7 million in a growing MRI business, a deal that underscores how hospitals are responding to cost-conscious patients.
A cancer patient received the first penis transplant in the U.S. and is recovering well from the delicate surgery, doctors said Monday.
EchoPixel likes to compare its 3-D imaging technology to cutting through a loaf of bread. MRIs and CT scans can create flat, two-dimensional pictures—or single slices—of information. But what if you wanted to cut into the loaf from a different angle to get more detailed cross sections?
NantHealth is starting to see greater insurance coverage for its molecular profile diagnostic test, GPS Cancer. The Culver City, Calif.-based company, which filed for an IPO earlier this week, needs to demonstrate that its approach to personalized medicine has commercial applications.